Hedge funds pull back from U.S. healthcare stocks as ACA fight intensifies

Goldman Sachs data, in a client note dated December 22, showed that hedge funds last week sold more U.S. healthcare stocks than they bought for the first time in 14 weeks, a reversal that traders and strategists said reflects mounting policy risk. The note also recorded a pronounced increase in short positioning across the sector, with short bets outweighing long positions by more than eight to one.

Within the healthcare complex the flows were uneven. Life sciences and healthcare technology were the only sub sectors where hedge funds were net buyers during the reported week. By contrast funds were net sellers of healthcare providers and services, and of pharmaceutical and biotechnology firms. That pattern points to a tactical withdrawal from companies whose near term cash flows depend on insurance payouts and reimbursement rates, while retaining exposure to firms seen as product oriented or technology driven.

The proximate cause identified in the Goldman Sachs data is political uncertainty over the Affordable Care Act premium subsidies, which are scheduled to lapse on December 31. Lawmakers are actively debating cost control and funding options, but the lack of a clear path ahead as the year end approaches has heightened the risk premium on names tied closely to insurance economics. Hedge funds traditionally respond to such discrete policy windows by trimming exposure and increasing shorts to protect portfolios against a rapid reassessment of future earnings.

The week of net selling should be read against a longer trend of defensive accumulation into healthcare, rather than as a wholesale exit. Earlier market commentary from Finimize showed multi week buying that pushed hedge fund interest in healthcare to a nine month high and counted eight straight weeks of inflows. Those broader data painted healthcare as a safe haven amid the weakest U.S. consumer sentiment in over three years and rising layoffs, trends that have encouraged some investors to rotate into defensible revenue streams. Goldman Sachs data suggests that within that longer term allocation, funds executed a short term pullback driven by immediate political risk.

From a market perspective the surge in short exposure is notable because it amplifies the potential for downward pressure if the subsidy impasse continues or if lawmakers signal tougher cost containment measures. Large short positions can steepen sell offs and increase volatility if sentiment shifts suddenly. For insurers and services companies, even temporary uncertainty about subsidies can affect enrollment, premium flows, and provider negotiating leverage in the coming months.

The Goldman Sachs note leaves key questions unanswered. It does not name specific hedge funds, disclose dollar amounts, or quantify the absolute size of short positions beyond the ratio. Investors will be watching congress and the executive branch for any stop gap measures before the December 31 deadline, and monitoring next week flows to see whether the selling episode is a brief tactical pause or the start of a broader reassessment of healthcare allocations heading into 2026.